MarketPulse

ODM-212

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Orion Corporation

Orion Lifts 2026 Outlook After Strong Q1 Surge Driven by Nubeqa Royalties

Finnish pharma $ORION reported 17.8% Q1 revenue growth to €417.7M, raised full-year guidance citing Nubeqa royalties and pipeline progress.
OECrevenue growthclinical trial
GlobeNewswire Inc.GlobeNewswire Inc.··Orion Corporation

Orion Surges on Strong Q1 Results, Raises 2026 Outlook Amid Pipeline Advances

Orion posts strong Q1 with 17.8% revenue growth, 47.3% operating profit surge, and raises 2026 outlook. Pipeline advances boost investor confidence.
BAYRYclinical trialsorphan drug designation